Showing results (121-130 of 183) with videos related to

Sort By:
Pageof 19
Neurochemistry International|May 22, 2010
Plasma and erythrocyte membrane long chain polyunsaturated fatty acids in endogenous depressionA M Fehily, O A Bowey, F R Ellis, et al.
Thrombosis and Haemostasis|April 8, 1998
Sex differences in the determinants of fibrinolytic activityP K MacCallum, J A Cooper, D J Howarth, et al.
European Heart Journal|August 1, 1988
Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot studyT W Meade, H C Wilkes, Y Stirling, et al.
Thrombosis Research|October 15, 1983
Haemostatic changes following surgeryC J Hawkey, Y Stirling, R Chakrabarti, et al.
Thrombosis and Haemostasis|August 2, 1993
Positive association between self-reported fatty food consumption and factor VII coagulant activity, a risk factor for coronary heart disease, in 4246 middle-aged menJ B Connelly, P J Roderick, J A Cooper, et al.
British Journal of Haematology|November 4, 2004
Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarctionPeter K MacCallum, Alicja R Rudnicka, Ann Rumley, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1994
Changes in clot deformability--a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarctionM C Scrutton, S B Ross-Murphy, G M Bennett, et al.
BMJ (Clinical Research Ed.)|April 24, 1999
Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based studyA J Welton, M R Vickers, J A Cooper, et al.
BMJ (Clinical Research Ed.)|August 20, 1988
Reduction in hospital readmission stay of elderly patients by a community based hospital discharge scheme: a randomised controlled trialJ Townsend, M Piper, A O Frank, et al.
Atherosclerosis|June 6, 2002
Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trialY Jamshidi, D M Flavell, E Hawe, et al.
Pageof 19